NASDAQ:GILD - Gilead Sciences News Headlines

Sign in or create an account to add this stock to your watchlist.
$65.55 -1.43 (-2.13 %)
(As of 02/21/2019 04:00 PM ET)
Previous Close$66.98
Today's Range$65.24 - $66.96
52-Week Range$60.32 - $82.71
Volume5.61 million shs
Average Volume7.77 million shs
Market Capitalization$84.80 billion
P/E Ratio10.66
Dividend Yield3.40%
Beta1.19

Headlines

Gilead Sciences (NASDAQ GILD) News Headlines

Source:
DateHeadline
What Analysts Are Recommending for GILD and ABBV in FebruaryWhat Analysts Are Recommending for GILD and ABBV in February
finance.yahoo.com - February 21 at 3:13 PM
GILD or ABBV: Which Is Expected to Report Faster EPS Growth?GILD or ABBV: Which Is Expected to Report Faster EPS Growth?
finance.yahoo.com - February 21 at 3:13 PM
2 Frustrating Flops, Plus Welcome to the Wrinkle Wars2 Frustrating Flops, Plus Welcome to the Wrinkle Wars
www.fool.com - February 21 at 10:16 AM
Insider Selling: Gilead Sciences, Inc. (GILD) Director Sells 19,068 Shares of StockInsider Selling: Gilead Sciences, Inc. (GILD) Director Sells 19,068 Shares of Stock
www.americanbankingnews.com - February 20 at 8:16 PM
Biotech Stock Roundup: ICPT Strong on NASH Drug Data, Collaborations & MoreBiotech Stock Roundup: ICPT Strong on NASH Drug Data, Collaborations & More
finance.yahoo.com - February 20 at 3:10 PM
Global Human Immunodeficiency Virus (HIV) Drugs Market 2019-2025 with AbbVie, Merck, Gilead Sciences, Bristol-Myers Squibb, Janssen & GSK DominatingGlobal Human Immunodeficiency Virus (HIV) Drugs Market 2019-2025 with AbbVie, Merck, Gilead Sciences, Bristol-Myers Squibb, Janssen & GSK Dominating
www.prnewswire.com - February 20 at 11:20 AM
Can Gilead Recover After Latest Earnings Downfall?Can Gilead Recover After Latest Earnings Downfall?
seekingalpha.com - February 20 at 5:11 AM
Gileads Recent NASH Trial Failure Represents Opportunity For GalectinGilead's Recent NASH Trial Failure Represents Opportunity For Galectin
seekingalpha.com - February 20 at 5:11 AM
Gilead Receives Approval in Canada for YESCARTA™ (Axicabtagene Ciloleucel) CAR T Therapy for Adults With Relapsed or Refractory Large B-cell Lymphoma After Two or More Lines of Systemic TherapyGilead Receives Approval in Canada for YESCARTA™ (Axicabtagene Ciloleucel) CAR T Therapy for Adults With Relapsed or Refractory Large B-cell Lymphoma After Two or More Lines of Systemic Therapy
finance.yahoo.com - February 19 at 3:14 PM
Intercept Shares Soar To Multimonth High After NASH Drug Aces Late-Stage TrialIntercept Shares Soar To Multimonth High After NASH Drug Aces Late-Stage Trial
finance.yahoo.com - February 19 at 3:14 PM
Intercept Comes in First With Liver Drug, But Race Isn’t OverIntercept Comes in First With Liver Drug, But Race Isn’t Over
finance.yahoo.com - February 19 at 3:14 PM
After Gilead Failed, Intercept Stock Rises On NASH Treatment StudyAfter Gilead Failed, Intercept Stock Rises On NASH Treatment Study
finance.yahoo.com - February 19 at 3:14 PM
Gilead Sciences (GILD) versus Avrobio (AVRO) Critical ContrastGilead Sciences (GILD) versus Avrobio (AVRO) Critical Contrast
www.americanbankingnews.com - February 17 at 1:16 AM
U.S. Medicare plans to track CAR-T cancer therapy outcomesU.S. Medicare plans to track CAR-T cancer therapy outcomes
finance.yahoo.com - February 15 at 3:10 PM
Gilead Could Be The Winner From Washington States Winner-Take-All Hep C ProposalGilead Could Be The Winner From Washington State's Winner-Take-All Hep C Proposal
seekingalpha.com - February 15 at 5:09 AM
Gilead: What Just Happened?Gilead: What Just Happened?
seekingalpha.com - February 15 at 5:09 AM
Despite M&A Spree, Biotech ETFs Slide on Mixed EarningsDespite M&A Spree, Biotech ETFs Slide on Mixed Earnings
finance.yahoo.com - February 14 at 3:09 PM
$5.33 Billion in Sales Expected for Gilead Sciences, Inc. (GILD) This Quarter$5.33 Billion in Sales Expected for Gilead Sciences, Inc. (GILD) This Quarter
www.americanbankingnews.com - February 14 at 6:48 AM
Biotech Stock Roundup: Regeneron Impresses in Q4, Gilead Slumps, MacroGenics SoarsBiotech Stock Roundup: Regeneron Impresses in Q4, Gilead Slumps, MacroGenics Soars
www.zacks.com - February 13 at 3:15 PM
Gileads (GILD) Late-Stage Study on Liver Disease Drug FailsGilead's (GILD) Late-Stage Study on Liver Disease Drug Fails
finance.yahoo.com - February 13 at 5:11 AM
Dash for NASH trips up Gilead, but 'fatty liver disease' remains biotech targetDash for NASH trips up Gilead, but 'fatty liver disease' remains biotech target
finance.yahoo.com - February 13 at 5:10 AM
Notable Tuesday Option Activity: EA, GILD, NKENotable Tuesday Option Activity: EA, GILD, NKE
www.nasdaq.com - February 12 at 3:06 PM
Why Gilead’s Pain Is Intercept’s GainWhy Gilead’s Pain Is Intercept’s Gain
247wallst.com - February 12 at 3:06 PM
Gilead Sciences: Reaching An Inflection PointGilead Sciences: Reaching An Inflection Point
seekingalpha.com - February 12 at 3:06 PM
Gilead's Liver-Drug Setback Clouds  $35 Billion DreamGilead's Liver-Drug Setback Clouds  $35 Billion Dream
finance.yahoo.com - February 12 at 3:06 PM
Gileads Failed NASH Drug Trial Drags Stock LowerGilead's Failed NASH Drug Trial Drags Stock Lower
finance.yahoo.com - February 12 at 3:06 PM
Gilead Sciences Stock Tumbles After Being Hit With Disappointing Trial DataGilead Sciences Stock Tumbles After Being Hit With Disappointing Trial Data
finance.yahoo.com - February 12 at 3:06 PM
Viking Therapeutics Breaks Out After Gilead's Clinical FailureViking Therapeutics Breaks Out After Gilead's Clinical Failure
finance.yahoo.com - February 12 at 3:06 PM
Gilead Flops In Liver Disease — Does Its Second Shot Have A Chance?Gilead Flops In Liver Disease — Does Its Second Shot Have A Chance?
finance.yahoo.com - February 12 at 3:06 PM
Gilead Sciences Falls on Failed Cirrhosis Drug Trial of SelonsertibGilead Sciences Falls on Failed Cirrhosis Drug Trial of Selonsertib
finance.yahoo.com - February 12 at 3:06 PM
Here's Why Viking Therapeutics Rose as Much as 13.9% TodayHere's Why Viking Therapeutics Rose as Much as 13.9% Today
finance.yahoo.com - February 12 at 3:06 PM
Gilead Sciences Stock Slides Lower on NASH Drug FailureGilead Sciences Stock Slides Lower on NASH Drug Failure
investorplace.com - February 12 at 1:36 PM
Citigroup Lowers Gilead Sciences (GILD) to NeutralCitigroup Lowers Gilead Sciences (GILD) to Neutral
www.americanbankingnews.com - February 12 at 12:13 PM
Raymond James Trims Gilead Sciences (GILD) Target Price to $85.00Raymond James Trims Gilead Sciences (GILD) Target Price to $85.00
www.americanbankingnews.com - February 12 at 12:08 PM
Gilead Sciences, Inc. (GILD) Expected to Announce Earnings of $1.62 Per ShareGilead Sciences, Inc. (GILD) Expected to Announce Earnings of $1.62 Per Share
www.americanbankingnews.com - February 12 at 7:12 AM
Gilead stock down nearly 4% as drug trial fizzlesGilead stock down nearly 4% as drug trial fizzles
www.marketwatch.com - February 12 at 5:04 AM
Gileads selonsertib flunks late-stage NASH studyGilead's selonsertib flunks late-stage NASH study
seekingalpha.com - February 12 at 5:04 AM
Gilead Announces Topline Data From Phase 3 STELLAR-4 Study of Selonsertib in Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)Gilead Announces Topline Data From Phase 3 STELLAR-4 Study of Selonsertib in Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
finance.yahoo.com - February 12 at 5:04 AM
Short Interest in Gilead Sciences, Inc. (GILD) Declines By 14.0%Short Interest in Gilead Sciences, Inc. (GILD) Declines By 14.0%
www.americanbankingnews.com - February 12 at 3:40 AM
Wells Fargo & Co Downgrades Gilead Sciences (GILD) to Market PerformWells Fargo & Co Downgrades Gilead Sciences (GILD) to Market Perform
www.americanbankingnews.com - February 11 at 8:40 PM
[$$] Big Pharma’s Big Cancer Hope Is Fizzling[$$] Big Pharma’s Big Cancer Hope Is Fizzling
finance.yahoo.com - February 10 at 8:11 PM
Why Gilead Sciences Stock Perked Up in JanuaryWhy Gilead Sciences Stock Perked Up in January
www.fool.com - February 10 at 12:12 PM
Why Agenus Inc. Stock Took Flight in JanuaryWhy Agenus Inc. Stock Took Flight in January
finance.yahoo.com - February 8 at 3:04 PM
Q1 2019 EPS Estimates for Gilead Sciences, Inc. (GILD) Cut by AnalystQ1 2019 EPS Estimates for Gilead Sciences, Inc. (GILD) Cut by Analyst
www.americanbankingnews.com - February 8 at 7:10 AM
Gilead Sciences, Inc. Expected to Post Q1 2019 Earnings of $1.43 Per Share (GILD)Gilead Sciences, Inc. Expected to Post Q1 2019 Earnings of $1.43 Per Share (GILD)
www.americanbankingnews.com - February 8 at 7:10 AM
Gilead Sciences, Inc. Forecasted to Post Q1 2019 Earnings of $1.56 Per Share (GILD)Gilead Sciences, Inc. Forecasted to Post Q1 2019 Earnings of $1.56 Per Share (GILD)
www.americanbankingnews.com - February 8 at 7:10 AM
Svb Leerink Brokers Reduce Earnings Estimates for Gilead Sciences, Inc. (GILD)Svb Leerink Brokers Reduce Earnings Estimates for Gilead Sciences, Inc. (GILD)
www.americanbankingnews.com - February 7 at 8:08 AM
Gilead: What A Difference An ODay Can MakeGilead: What A Difference An O'Day Can Make
seekingalpha.com - February 7 at 5:07 AM
4 New CEOs to Watch in 20194 New CEOs to Watch in 2019
finance.yahoo.com - February 6 at 3:14 PM
Analysts Focus On Gileads Late-Stage Data Readouts Following Mixed Q4Analysts Focus On Gilead's Late-Stage Data Readouts Following Mixed Q4
finance.yahoo.com - February 6 at 5:18 AM
This page was last updated on 2/21/2019 by MarketBeat.com Staff

Featured Article: Municipal Bonds

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel